EXELIXIS, INC.EXEL

Market cap

$11.6B

P/E ratio

	Dec 31, 2011	Dec 31, 2012	Dec 29, 2017	Dec 28, 2018	Jan 3, 2020	Jan 1, 2021	Dec 31, 2021	Dec 30, 2022	Dec 29, 2023	Jan 3, 2025
Cash and cash equivalents	74	170	183	315	267	319	647	501	263	217
Marketable securities	120	483	205	379	586	887	820	807	1,465	894
Trade receivables, net	-	-	81	163	119	161	283	215	237	265
Inventory	-	-	7	10	13	21	27	33	17	22
Prepaid expenses and other current assets	4	6	9	15	27	57	58	62	68	68
Total current assets	229	433	485	897	1,011	1,445	1,835	1,619	1,318	1,468
Non-current marketable securities	85	182	64	157	536	332	371	757	729	637
Property and equipment, net	9	6	26	51	49	67	104	111	129	119
Deferred tax assets, net	-	-	-	244	172	157	112	231	361	420
Goodwill	64	64	64	64	64	64	64	64	64	64
Right-of-use assets and other non-current assets	-	-	-	-	-	-	-	-	-	240
Total assets	393	721	655	1,422	1,886	2,137	2,616	3,071	2,942	2,948
Accounts payable	2	4	10	11	12	24	24	33	34	38
Accrued compensation and benefits	9	10	21	32	37	51	62	77	93	110
Accrued clinical trial liabilities	-	-	20	18	39	52	78	65	72	58
Rebates and fees due to customers	-	-	8	15	19	21	34	50	60	62
Accrued collaboration liabilities	-	-	9	7	12	12	87	20	28	40
Other current liabilities	-	-	-	-	-	-	53	79	108	95
Total current liabilities	92	82	115	105	143	205	338	324	394	404
Operating Lease, Liability, Noncurrent	-	-	-	-	48	49	51	190	190	191
Other non-current liabilities	8	6	17	1	2	1	8	62	94	109
Total liabilities	303	425	370	135	200	258	406	583	678	703
Preferred Stock, Value, Issued	-	-	-	-	-	-	-	-	-	-
Common Stock, Value, Issued	0	0	0	0	0	0	0	0	0	0
Additional paid-in-capital	1,197	1,550	2,114	2,168	2,242	2,322	2,428	2,537	2,441	2,344
Accumulated other comprehensive loss	-0	-0	-0	-1	3	4	-1	-15	-4	-1
Accumulated deficit	-1,106	-1,254	-1,829	-880	-559	-448	-217	-34	-173	-99
Total stockholders’ equity	91	296	285	1,287	1,686	1,879	2,211	2,488	2,264	2,244
Total liabilities and stockholders’ equity	393	721	655	1,422	1,886	2,137	2,616	3,071	2,942	2,948